Differential expression of SUMO-specific protease 7 variants regulates epithelial–mesenchymal transition by Tasneem Bawa-Khalfe et al.
Differential expression of SUMO-specific protease 7
variants regulates epithelial–mesenchymal transition
Tasneem Bawa-Khalfea,1, Long-Sheng Lub, Yong Zuoc, Chao Huangb, Ruhee Dered, Feng-Ming Linb,
and Edward T. H. Yeha,b,1
aDepartment of Cardiology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030; bTexas Heart Institute/St. Luke’s Episcopal Hospital,
Houston, TX 77030; cDepartment of Biochemistry and Molecular Cell Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China;
and dCenter for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M Health Cancer Center, Houston, TX 77030
Edited by Avram Hershko, Technion Israel Institute of Technology, Haifa, Israel, and approved September 6, 2012 (received for review June 4, 2012)
Two Sentrin/small ubiquitin-like modifier (SUMO)-specific protease
7 (SENP7) variants are naturally expressed in breast epithelia. Breast
cancer (BCa) onset down-regulates the short SENP7 splice variant
(SENP7S) and enhances the long transcript (SENP7L). Here, we show
that SENP7L induction promotes gene expression profiles that favor
aberrant proliferation and initiate epithelial–mesenchymal transi-
tion (EMT). SENP7L exhibits an interaction domain for the epigenetic
remodeler heterochromatin protein 1 α (HP1α) and isopeptidase
activity against SUMO-modified HP1α. Loss of this interaction do-
main, as observedwith SENP7S, favors HP1α SUMOylation. SUMOy-
lated HP1α is enriched at E2F-responsive and mesenchymal gene
promoters, silences transcription of these genes, and promotes cel-
lular senescence. Elevated SENP7L renders HP1α hypo-SUMOylated,
which relieves transcriptional repression of the same genes and
concurrently decreases transcription of epithelial-promoting genes
via an HP1α-independent mechanism. Consequently, SENP7L levels
correlate with EMT, motility, and invasiveness of BCa cells. Stable
knockdown of elevated SENP7L levels lessens the dissemination of
highly metastatic BCa cells to the lungs from primary implantation
sites in in vivo studies. Thus, differential splicing of the SENP7 reg-
ulates either tumor suppression or progression.
posttranslational-modification | epigenetics | dedifferentiation
Posttranslational modification by the small ubiquitin-like mod-ifier (SUMO) family has garnered much attention in cancer
biology. This could be attributed to the ability of SUMOylation to
elicit a rapid and reversible change to a protein’s function and/or
subcellular localization. However, SUMOylation of one cellular
target may be critical for normal cell physiology, whereas SUMO
conjugation of another protein may promote aberrant growth.
Hence, targeting the SUMO-conjugating machinery may be det-
rimental to cancer as well as normal cells.
Recently, the interest has shifted to the SUMO deconjugating
enzymes or Sentrin/SUMO-specific proteases (SENP), which ex-
hibit isopeptidase activity against a select subset of SUMOylated
substrates. Although the expression of several SENPs is altered
with onset of various carcinomas (1, 2), the physiological and/or
pathophysiological function of many of the SENPs remains un-
defined. In addition, the six mammalian SENPs exhibit multiple
splice variants that add to the functional diversity of the individual
enzymes. SENP7 is an ideal example. Our laboratory used both
extrinsic and experimental approaches to identify an SENP7 gene
transcript with an intact catalytic domain (3). Recent studies show
that the catalytic domain of SENP7 exhibits activity against syn-
thetic and endogenous SUMO-conjugated substrates (4–6). Al-
though these studies demonstrate SENP7’s deSUMOylating
capabilities, there exists a paucity of literature on the biological
function of SENP7. In the present article we characterize two
SENP7 transcript variants whose dueling functions support either
tumor suppressive or potentiating pathways. To initiate a specific
pathway, the SENP7 isoforms modulate differential epigenetic
profiles in cancer cells.
The chromobox (CBX) homolog superfamily consists of well-
characterized epigenetic remodeling proteins. Recently we dem-
onstrated that SENP2-mediated deSUMOylation is critical for
directing the function of CBX4/Pc2 in development (7). SUMOy-
lation of other CBX proteins, specifically the heterochromatin
protein 1 (HP1) isoforms, regulates their heterochromatic locali-
zation and subsequent gene silencing functions that maintain
normal cell biology (8, 9). Clearly SUMO modification regulates
the function of CBX proteins; however, it is unknown how
SUMOylation of CBX proteins contributes to the epigenetic
reprogramming of cancer cells. In cancer biology, CBX5/HP1α
dictates the invasive nature of breast cancer (BCa) cells (10). Ex-
pression of HP1α, unlike the other isoforms, correlates with BCa
onset and enhanced diagnosis of cancer metastasis (11, 12). To
acquire invasive properties and initiate the metastatic cascade,
cancer cells repress epithelial genes and elicit de novo transcription
of mesenchymal genes to promote epithelial–mesenchymal tran-
sition (EMT) (13). Although previous studies suggest that HP1α
directs BCa invasiveness, the ability of HP1α to establish gene
profiles that favor EMT has not been investigated. The present
study demonstrates that SENP7 variants dictate the level of HP1α
SUMOylation, which in turn contributes to epigenetic reprog-
ramming for EMT.
Results
Since our initial report (3), two SENP7 transcript variants have
been validated in the RefSeq database (Fig. 1A); the full-length
SENP7 mRNA (SENP7L, accession no. NM_020654.3) and a
shorter exon 6-deficient variant (SENP7S, accession no.
NM_001077203.1). SENP7L and SENP7S are expressed differ-
ently in normal human breast epithelia, with tissue from in-
dependent patient samples exhibiting substantially greater
mRNA of splice variant SENP7S than of SENP7L (Fig. 1B).
Expression of SENP7L in breast epithelia is comparable to levels
found in other tissues (Fig. S1A). As opposed to all SENP7
transcripts (Fig. S1B), the SENP7L message increases with the
onset of nonmetastatic BCa in human patient samples (P < 0.05;
Fig. 1C). Tumor metastasis further potentiates SENP7L mRNA
levels in the primary tumor samples (P = 0.05 vs. nonmetastatic
carcinoma samples; Fig. 1C) and prompts SENP7L to become
the major SENP7 transcript (Fig. S1 C and D). In contrast,
SENP7S is reduced in BCa patients (either non- or metastatic
carcinoma vs. normal, P < 0.05; Fig. 1D). A similar trend is
observed at a cellular level with elevated SENP7L mRNA in
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highly metastatic human BCa cell lines (MDA-MB-231, GI101a,
GILM2) compared with normal MCF10-2A (Fig. 1E). Collec-
tively, the data indicate that SENP7S is the dominant in normal
breast tissue, whereas SENP7L is elevated in aggressive carci-
nomas. Hence, we sought to determine whether the increase in
the SENP7L variant could play a role in BCa pathogenesis.
Yeast two-hybrid analysis suggested association between SENP7L
and HP1α, and subsequent immunoprecipitation confirmed that
SENP7L, but not SENP7S, binds HP1α (Fig. S1E). This interac-
tion does not require catalytic activity: both the active wild-type
SENP7L and the catalytically inactive mutant (SENP7Lm) bind
endogenous HP1α efficiently (Fig. S1F). To identify the HP1α-
interaction domain on SENP7 transcripts, we first targeted the
PRVIL sequence as a canonical PXVXL motif (described in SI
Materials and Methods). This pentapeptide sequence is located on
exon 6 of SENP7 and consequently present on the SENP7L but
not SENP7S. PRVIL is conserved among mammals because it
appears on the N terminus of multiple full-length SENP7 ortho-
logs (Fig. 2A). When alanine replaces P, V, and L, SENP7L inter-
action with HP1α is lost; hence, SENP7L binds HP1α via a PXVXL
motif (Fig. 2B). The other five SENPs do not exhibit an analogous
PRVIL sequence.
Chromatin-bound HP1α is modified by endogenous SUMO2/3
but not SUMO1 with SENP7 reduction (Fig. 2C); targeted
siRNA and shRNA independently decrease SENP7 mRNA in
multiple human BCa cells (Fig. S2 A and B, respectively). In
contrast, all three SUMO isoforms conjugate HP1α in in vitro
conditions (Fig. 2D and Fig. S3A). SUMO2/3-conjugated HP1α
is readily observed in human BCa cells with less SENP7L tran-
script (MCF10-2A compared with GI101a or GILM2; Fig. S3B),
indicating an inverse correlation between HP1α SUMOylation
and SENP7L expression. Hence, we wanted to assess whether
SENP7L deSUMOylates HP1α more efficiently than the HP1α
interaction-deficient SENP7L mutant (PXVXLdf). Maximum
SUMOylation of endogenous HP1α was maintained with over-
expression of SUMO2 and the E3 ligase PIAS4 (lane 1 and 2,
Fig. 2D). SENP7L induction decreases SUMOylated HP1α levels
(lane 3, Fig. 2D, and lane 4, Fig. S3C), whereas inactive
SENP7Lm does not (lane 4, Fig. 2D). Similar to SENP7S (Fig.
S3C), the PXVXLdf mutant (Fig. 2B) also cannot deSUMOylate
modified HP1α (lane 5, Fig. 2D). Hence, the data suggest that an
intact catalytic domain and PXVXL sequence is required for
SENP7L to deSUMOylate HP1α.
When SUMO2 is elevated, the wild-type HP1α (HP1α-WT) is
recruited to trimethylated histone 3 K9 (H3K9m3) in MDA-MB-
231 cells (Fig. 3 A and B). To validate the importance of
SUMOylation in directing HP1α’s subnuclear localization, a
SUMO-deficient HP1α mutant (K32R) was generated (Fig. S3D).
Unlike HP1α-WT, K32R does not readily bind the silenced chro-
matin mark H3K9m3 (Fig. S3E), even under hyper-SUMOylation
conditions (Fig. 3 C and D). Therefore, unlike mutation of in-
dividual K residues in the HP1α hinge region, which causes
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Fig. 1. Inverse expression of two SENP7 transcripts with onset of BCa. (A)
Schematic illustrating the alternative exon 6 splicing (dashed lines below)
from the human SENP7 to generate two transcript variants (SENP7L and
SENP7S). SENP7L and SENP7S mRNA levels were assessed using specific pri-
mers (P1/P2 and P3/P4, respectively) for the highlighted regions. (B) Five
normal human mammary epithelia samples independently exhibit higher
SENP7S than SENP7L message. Data represent the fold change in SENP7S
compared with SENP7L mRNA levels. (C) An induction of SENP7L mRNA
occurs with nonmetastatic and metastatic carcinoma compared with normal
tissue (ANOVA and Dunnett’s, P < 0.05 and P < 0.001, respectively, n = 48).
SENP7L mRNA levels are greater in patients with metastatic than non-
metastatic disease (Student t test, P = 0.05). (D) The same samples exhibit
lower SENP7S mRNA with carcinoma (vs. normal tissue, ANOVA and Dun-
nett’s, P < 0.05). (E) Highly metastatic BCa cell lines MDA-MB-231, GI101a,
and GILM2 express higher SENP7L than SENP7S (n = 2–3). Data in C–E rep-
resent the fold change of the indicated transcript in cancer tissue or cells
compared with normal tissue or MCF710-2A cells.
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Fig. 2. SENP7L transcript interacts with chromatin-associated HP1α and
dictates the level of SUMO2/3-modified HP1α. (A) Schematic representation
of the HP1α interaction motif (PRVIL) on the human SENP7L with respect to
exon 6 and the catalytic domain. Alignment of the human SENP7L with
other mammalian full-length SENP7 orthologs indicates conservation of the
PXVXL sequence. (B) The interaction of Flag-tagged SENP7L and HA-HP1α
was confirmed with independent pull-down experiments in COS cells. HP1α
interaction is lost with mutation of the PRVIL sequence to ARAIA on the
SENP7L. (C) After siSENP7 knockdown for 48 h, endogenous SUMO2/3
modification of chromatin-bound HP1α was observed in MCF7 cells. (D)
SUMOylation of endogenous HP1α is modestly potentiated with PIAS4 (lane
2) in MCF7 cells. SUMO-modified HP1α is reduced by SENP7L (lane 3) but not
inactive SENP7Lm (lane 4) or HP1α interaction-deficient PXVXLdf (lane 5).
Asterisks highlight SUMO-conjugates in C and D.
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residual SUMOylation at alternative sites (8), the SUMOylation of
K32 within the chromodomain of HP1α seems to be unique in that
it is critical for HP1α to bind H3K9m3. Hence, the K32 site is
similar to the SUMO acceptor site on the chromodomain of the
fission yeast HP1 homolog Swi6, which prevents localization to
heterochromatic regions when deleted (9).
Endogenous HP1α is defused throughout the nucleus and binds
H3K9m3 primarily in condensed chromatin regions, which are
heavily DAPI-stained (white arrow on final panel, Fig. 3E), in
nontargeting siRNA (siNT)-treatedMCF7 cells. However, SENP7
knockdown concentrates HP1α’s distribution (Fig. 3E and Fig.
S4A) and enhances HP1α-H3K9m3 association (Fig. 3 E and F).
This interaction occurs both within (white arrow, Fig. 3E) and
outside (yellow arrows, Fig. 3E) condensed chromatin regions.
SUMO3-fused HP1α (SUMO3-HP1α) constructs also appear in
similar concentrated loci but under native conditions (Fig. S4 B
and C). Whereas HP1α-WT is present on the chromosome in a
speckled pattern, SUMO3-HP1α is uniformly distributed at
H3K9m3 loci throughout both chromosome arms (yellow arrow-
heads, Fig. 3G) and at the pericentric region (highlighted circle,
Fig. 3G). Hence, SUMO3-HP1α more efficiently binds H3K9m3-
rich domains than HP1α-WT (Fig. 3H).
To see whether SUMOylation affects HP1α’s recruitment to
specific gene loci, we conducted a series of ChIP experiments
that evaluated HP1α’s localization at the promoter of previously
identified HP1α-target genes (14–16). SENP7-targeted siRNA
(siSENP7) enriches HP1α at the promoter of proliferation-reg-
ulating E2F-response genes dihydrofolate reductase (DHFR),
thymidylate synthase (TS), and CDC25a (Fig. 4A). Although
HP1α is present at the E2F-unresponsive c-fos promoter under
native conditions, reducing SENP7 does not increase HP1α
levels at the c-fos promoter (Fig. 4A). Therefore, the data sug-
gest that SENP7 loss prompts HP1α’s enrichment selectively at
E2F-responsive gene promoters.
Because HP1α modulates BCa cell invasiveness (10), we as-
sessed HP1α’s presence at the promoter of the invasion-regulating
vimentin under normal and reduced SENP7 conditions. HP1α
binds the vimentin promoter at detectable levels in siNT-treated
MCF7 cells (Fig. 4A), whereas SENP7 loss elevates the recruitment
of HP1α to this mesenchymal gene promoter (Fig. 4A). In contrast,
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Fig. 3. SUMOylation regulates HP1α chromatin localization. (A) The V5-
tagged HP1α-WT more readily colocalizes with H3K9m3 in the presence of
SUMO2 for 48 h in MDA-MB-231 cells. (B) Graph shows that SUMO2 over-
expression increases HP1α-H3K9m3 interaction in multiple MDA-MB-231
cells (n = 8–9, Student t test, P < 0.01). (C and D) Hyper-SUMO conditions do
not alter V5-K32R-H3K9m3 association in the same cell line (n = 6–7). (E and
F) Endogenous HP1α colocalizes with H3K9m3 more efficiently after siSENP7,
but not siNT, treatment in MCF7 cells (n = 8–9, Student’s test, P < 0.01). This
interaction occurs inside (white arrow) and outside (yellow arrow) highly
condensed chromatin, which is highlighted by intense DAPI staining. (G and
H) SUMO3-HP1α binds H3K9m3-rich loci throughout the chromosome (yel-
low arrowhead) and near the centromere (highlighted with a circle) more
efficiently than HP1α-WT.
DHFR TS CDC25a c-fos
0
1
2
3
4
10
40
70 HP1 -wt
HP1 -wt + SUMO3
SUMO3-HP1
Promoters
C
hI
P 
fo
r 
H
P1
B C
0
1
2
3
4
100
125
150
HP1 -wt
HP1 -wt + SUMO3
K32R
K32R + SUMO3
SUMO3-HP1
Vimentin Promoter
C
hI
P 
fo
r 
H
P1
D
SENP7 DHFR TS Vimentin Fibronectin N-cadherin E-cadherin Claudin 
0
1
2
3
4
10
30
50 Respective Control
siSENP7
PXVXLdf
SENP7L* *
* p<0.05
Mesenchymal Epithelial
*
* *
E2F-Responsive
Fo
ld
 C
ha
ng
e 
in
 m
RN
A
(D
el
ta
 D
el
ta
 C
t)
A
DHFR Promoter
Thymidylate Synthase Promoter
CDC25a Promoter
c-fos Promoter
Vimentin Promoter
E-cadherin Promoter
si
N
T
si
SE
N
P7
si
N
T
si
SE
N
P7
si
N
T
si
SE
N
P7
Input H3K9m3 P
ChIP
E2F-responsive
EMT Markers
Fig. 4. SENP7L and concomitantly SUMOylation define HP1α’s recruitment
to specific gene promoters and gene silencing function. (A) ChIP with either
H3K9m3 or HP1α antibody was followed by RT-PCR (representative of three
independent experiments). Knockdown with siSENP7 but not siNT in MCF7
cells for 48 h enhances HP1α recruitment at E2F-regulated gene and
Vimentin promoters; it also induces H3K9m3 at the same promoters. (B)
Real-time PCR of ChIP samples (n = 3) indicates that SUMO3 overexpression
enriches HP1α-WT at E2F-responsive gene promoters (DHFR, TS, and cdc25a)
but not the E2F-unresponsive c-fos promoter in MDA-MB-231 cells; the
SUMO3-HP1α construct exhibits a similar distribution pattern. (C) SUMO3-
HP1α’s presence is substantially greater than HP1α-WT at the Vimentin
promoter as observed in independent ChIP experiments (n = 3). K32R
mutants do not bind the Vimentin promoter, and no change occurs with
SUMO3 overexpression in MDA-MB-231 cells. (D) Real-time PCR analysis of
MCF7 cells indicates that SENP7, compared with NT, siRNA treatment lowers
E2F-responsive and mesenchymal mRNA but increases the mRNA of epi-
thelial markers. SENP7L overexpression elevates E2F-responsive and mesen-
chymal mRNA compared with EV. Student t test suggest a significant
difference between SENP7L and PXVXLdf mutant (n = 5, P ≤ 0.05).
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HP1α does not bind the epithelial-inducing E-cadherin (E-cad)
promoter after either siNT or siSENP7 treatment.
SUMO3 overexpression in MDA-MB-231 cells produces a
similar HP1α recruitment to E2F-responsive genes and vimentin
(Fig. 4 B and C, respectively), but not c-fos, promoters (Fig. 4B).
SUMO3-HP1α exhibits an even greater affinity for these same
promoters than HP1α-WT (Fig. 4 B and C). Whereas HP1α-WT
binds the vimentin promoter under native conditions, K32R does
not (Fig. 4C). Even hyper-SUMOylation conditions cannot force
K32R to vimentin (Fig. 4C) or E2F-regulated gene promoter
(Fig. S4D), suggesting that this SUMO acceptor site is required
for HP1α’s recruitment to specific promoters.
Interestingly, HP1α’s enrichment at E2F-responsive and
vimentin gene promoters occurs concurrently with enhanced
H3K9m3 near these same promoters (Fig. 4A). Induction of this
silenced chromatin mark at the promoter loci suggests tran-
scriptional repression of these genes with SENP7 knockdown.
This is indeed the case: mRNA levels of DHFR, TS, vimentin,
and two additional mesenchymal markers (fibronectin and N-
cadherin) are reduced after siSENP7 in MCF7 cells (Fig. 4D).
The same mRNAs are reduced with expression of SUMO3-
HP1α in MDA-MB-231 cells (Fig. S4E).
Conversely, maintaining hypo-SUMOylated HP1α with over-
expression of SENP7L (Fig. 2E) elevates the mRNA of E2F-
responsive and mesenchymal genes (Fig. 4D). In contrast, in-
creasing PXVXLdf exhibits lower DHFR, TS, vimentin, fibro-
nectin, and N-cadherin mRNA levels than SENP7L (P < 0.05,
Student t test; Fig. 4D) but comparable to empty vector (EV)
control. Although elevated after siSENP7, the mRNA of epi-
thelial markers E-cad and claudin is repressed by overexpression
of either SENP7L WT or PXVXLdf mutant (Fig. 4D). SENP7
reduction also enhances E-cad mRNA inMDA-MB-231 cells, but
SUMO3-HP1α does not alter E-cad mRNA (Fig. S4E). Hence, it
seems that SENP7L modulates the mRNA levels of epithelial-
promoting genes via an HP1α-independent mechanism.
Interestingly, long-term (120 h) SENP7 knockdown causes
enlarged flattened cells with intracellular vacuoles (Fig. S5A),
reminiscent of senescence cell morphology. SENP7 loss causes
additional hallmark signs of senescent cells; specifically, siSENP7-
treated cells exhibit β-gal staining (Fig. 5 A and B), senescence-
associated heterochromatin foci as indicated by concentrated
DAPI and H3K9m3 staining (Fig. 5 C and D), decreased cell
growth (Fig. S5B), and MNase-insensitive condensed chromatin
(Fig. S5C).
Transient SENP7L overexpression (48 h) causes MCF7 cells to
become irregular in shape and more loosely dispersed than the
tightly clustered cells transfected with either EV or SENP7Lm
(Fig. 5E). Cells with elevated SENP7L instead resemble TGF-
β–treated MCF7 cells (Fig. 5 E and F). Previous studies have
demonstrated that TGF-β treatment causes EMT with transcrip-
tional repression of epithelial-promoting genes, including E-cad,
and activation of mesenchymal-inducing genes like vimentin (17,
18). Hence E-cad and vimentin expression was evaluated in MCF7
cells treated with TGF-β, or transfected with either EV or SENP7L.
Consistent with mRNA data (Fig. 4D), elevated SENP7L levels
caused a loss of E-cad equivalent to TGF-β treatment and prompted
vimentin expression unlike EV (Fig. 5G).
Consistent with the EMT morphology (Fig. 5G), over-
expression of SENP7L, but not PXVXLdf (Fig. S6A), enhances
motility of MCF7 control clones shNT-MCF7 (Fig. 6A). To fur-
ther determine whether the SENP7L transcript solely contributes
to the mesenchymal nature of cancer cells, we evaluated BCa cell
motility after knockdown of all catalytically active SENP7 tran-
scripts. Stable or transient SENP7 reduction significantly decreases
the migratory property ofMCF7 and two additional BCa cells (Fig.
6A and Fig. S6B). Overexpression of SENP7L completely rescues
the reduced motility of stable MCF7 clones with lower SENP7
levels (shSP7-MCF7, Fig. 6A). In contrast, neither SENP7S nor the
PXVXLdf altered the shSP7-MCF7 migration (Fig. S6C and
Fig. 6A, respectively). Because SENP7L-HP1α interaction is im-
portant for BCa cell motility, we assessed how changes to HP1α
SUMOylation affect motility. MCF7 clones treated with HP1α-
targeted siRNA (siHP1α) exhibited massive amounts of cell death.
Consequently, to ensure adequate HP1α levels for cell survival,
siHP1α was combined with transfection of either HP1α-WT or
K32R (Fig. S6D). When supplemented with HP1α-WT, shSP7-
MCF7 clones are less motile than shNT-MCF7 (Fig. 6B) and re-
semble EV-transfected shSP7-MCF7 (Fig. 6A). Although K32R
expression enhances shSP7-MCF7 motility, the migratory property
of these cells is less thanHP1α-WT–expressing shNT-MCF7 clones
(Fig. 6B).
Similarly, reducing all catalytically active SENP7 isoforms
prompts a reduction in GILM2 cells’ invasiveness (Fig. 6C).
Diminished GILM2-shSENP7 invasiveness is completely rever-
ted with SENP7L expression (Fig. 6C), suggesting that SENP7L
is the sole transcript required for the invasive and migratory (Fig.
6A) property of BCa cells. Consequently, we postulated that
decreasing the large SENP7L population present natively in
GILM2 cells (Fig. 1E) should affect the tumorigenic and meta-
static potential of these aggressive BCa cells. When injected into
the mammary fat pad of nude mice with their respective controls,
GILM2-shSENP7 cells produce smaller primary tumors in xen-
ografts compared with GILM2-shNT control cells (P < 0.05,
Student t test; Fig. 6D). Similar results are obtained in GI101a
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Fig. 5. SENP7L regulates cellular senescence and EMT. Exposure of MCF7
cells to SENP7 siRNA for 120 h increases β-galactosidase uptake (A and B) and
condensed chromatin as observed with DAPI and H3K9m3 staining (C and D).
(E and F) Both transient (48 h) SENP7L and TGF-β (10 ng/mL) treatments
produced more dispersed, stellated MCF7 cells (defined as EMT morphology)
compared with EV (ANOVA and Tukey’s, P < 0.05 and P < 0.01, respectively);
SENP7L mutant transfection had no effect. (G) Immunofluorescence evalu-
ation indicated reduced E-cad and simultaneous increased Vimentin after
both treatments compared with EV treatment. Each image is representative
of three to four independent experiments.
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cells (P ≤ 0.01, Student t test; Fig. S6D). Gene expression
analysis indicates lower mRNA of E2F-responsive genes and
vimentin in tumor mass from GI101a-shSENP7 and GILM2-
shSENP7 than their respective shNT control xenografts (Fig.
S6F), similar to results from cultured cells (Fig. 4D).
Four weeks after removal of 12-mm-diameter primary tumors,
lung tissue harvested from GILM2-shNT exhibited a greater
number (n = 11) of metastatic lesions than GILM2-shSENP7
(n = 5) xenografts. The metastatic foci were also smaller in
GILM2-shSENP7 thanin GILM2-NT xenografts (P < 0.01, Stu-
dent t test; Fig. 6 E and F). Hence, the elevated SENP7L found
in GILM2 cells are critical for its metastatic capability.
Discussion
Two SENP7 transcripts exhibit inverse expression and function in
breast cells. The shorter splice variant, SENP7S, is highly expressed
in normal breast cells (Fig. 1B), whereas SENP7L is augmented in
BCa cells (Fig. 1 C and E and Fig. S1C). Fluctuation of specific
variants is a common event that contributes to the complexity of the
cancer environment. SENP7L induction and concomitant SENP7S
loss could occur via multiple mechanisms. First, the SENP7 se-
quence could undergo mutations that prevent recognition of splice
sites that facilitate generation of SENP7S. Second, BCa onset may
causes changes in the splicing machinery, specifically reduction of
splicing enhancers and induction of splicing silencers. Exactly
which mechanism contributes to SENP7L enhancement is beyond
the scope of this article but needs to be investigated further.
Clearly maintaining elevated SENP7L levels is beneficial for
cancer cells because SENP7L orchestrates three events: (i)
overcoming the growth barriers, (ii) de novo mesenchymal gene
expression, and (iii) repressing transcription of epithelial genes.
The first two events are dependent on HP1α deSUMOylation.
The PXVXL sequence of SENP7L is required for interaction
with HP1α and deSUMOylation of HP1α in human BCa cells
(Fig. 2 B and D). As we were preparing this report, a brief
communication also reported an interaction between SENP7
and HP1α in mouse fibroblast cells but did not identify the
PXVXL motif or its significance to HP1α SUMOylation (6). The
authors did demonstrate that reducing SENP7 levels in these
fibroblast cells decreases HP1α’s recruitment to the H3K9m3-
rich pericentric region (6). In contrast, HP1α-H3K9m3 associa-
tion is enhanced with reduction of SENP7 (Fig. 3F) or under
hyper-SUMOylation conditions (Fig. 3B) in human BCa cells.
Consistently, SUMO3-HP1α constructs are readily localized with
H3K9m3 at and outside the pericentric region (Fig. 3 G and H).
The difference between the previous results and our present
findings could be due to the different species of cells, the SUMO
isoform conjugated to HP1α, or different regulatory mechanisms
that persist with HP1α-SENP7 interaction in normal vs. cancer
cells. It is also intriguing to speculate that an additional unchar-
acterized SENP7 transcript may be present in the mouse fibro-
blast, but not human BCa, cells.
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Fig. 6. Induction of SENP7L contributes to the tumorigenic property of BCa
cells. (A) Stable shRNA-expressing MCF7 clones were transiently transfected
with the indicated plasmid. EV-transfected shNT-MCF7 clones are signifi-
cantly different from SENP7L-transfected shNT-MCF7, EV-transfected shSP7-
MCF7, and PXVXLdf-transfected shSP7-MCF7 clones (ANOVA and Dunnett’s,
P < 0.05). Brackets indicate Student t test results for comparison of specific
treatment groups. Data represent mean ± SEM from three to four in-
dependent experiments. (B) Endogenous HP1α was down-regulated with
HP1α-targeting siRNA and simultaneously replaced by transfection of either
HP1α-WT or K32R. The shSP7-MCF7 cells with either WT or K32R are less
motile than shNT-MCF7 cells with HP1α-WT (ANOVA and Dunnett’s, P < 0.05,
n = 3), but K32R does slightly enhance shSP7-MCF7 motility compared with
HP1α-WT expression (Student t test, P ≤ 0.05). (C) Invasion through extra-
cellular matrix is decreased in stable GILM2-shSENP7 (n = 3, Student t test,
P < 0.001); this is reverted with SENP7L overexpression. (D) GILM2-shSENP7
(n = 10) produced dramatically smaller tumors in the mammary fat pad of
female nude mice than control GILM2-shNT (n = 6, Student t test, P ≤ 0.01).
(E and F) GILM2-shNT cells (n = 9) formed larger metastatic lesions in the
lung (Student t test, P < 0.01) than GILM2-shSENP7 (n = 5). An average
metastatic niche in lung tissue from the indicated xenograft is shown.
Fig. 7. SENP7L levels dictate BCa cells’ choice between senescence and EMT.
Onset of cancer in breast epithelia decreases the SENP7S splice variant and in-
creases SENP7L, which expresses an HP1α-interaction motif. Loss of SENP7L-
HP1α interaction causes HP1α hyper-SUMOylation, an enrichment of HP1α at
E2F-responsive and mesenchymal gene promoters, silences transcription of
these genes, and elicits cellular senescence. Induction of SENP7Lmaintains hypo-
SUMOylated HP1α, which relieves HP1α-mediated repression of proliferation-
promoting E2F-responsive genes as well as mesenchymal genes. SENP7L de-
creases epithelial gene expression via an unidentified HP1α-independent
pathway (dashed line), and concurrently with the HP1α-dependent pathway
promotes dedifferentiation.
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In human BCa cells, SUMO modification also directs HP1α to
specific promoter loci (Fig. 4). When present at E2F-reponsive
gene promoters, HP1α enhances the recruitment of other chro-
matin regulators, including histone methyltransferases, and
potentiates H3K9m3 to silence E2F-responsive genes (14–16,
19). The present data show that HP1α SUMOylation enriches it
at E2F-responsive gene promoters (Fig. 4 A and B) and represses
transcription of these genes (Fig. 4D and Fig. S4E). Silencing
E2F-responsive genes causes cellular senescence irrespective of
upstream mediators like p53 and Rb (14, 20). Therefore, because
SENP7 knockdown suppresses E2F-responsive gene transcrip-
tion (Fig. 4D), it is not surprising that SENP7 loss causes cellular
senescence in BCa cells (Fig. 5 A–D).
Recent studies suggested that senescence of cancer cells is
modulated by transcription factors that initiate EMT; loss of
these transcription factors prevents EMT and elicits cellular se-
nescence (21, 22). The mechanism for simultaneous regulation of
both processes was presented as “collateral damage” and hence
remains poorly defined. Like these transcription factors, chro-
matin-remodeling proteins are also capable of facilitating the
EMT response (23, 24). In the present study we demonstrate that
the interaction of SENP7L with HP1α and consequently HP1α’s
SUMOylation state dictates both cellular senescence and de novo
mesenchymal gene transcription in BCa cells. SENP7 knockdown
enhances HP1α’s enrichment at the vimentin promoter and
reduces vimentin and additional mesenchymal transcripts (Fig. 4
A, C, and D). Conversely, MCF7 cells, which are epithelium-like,
exhibit de novo transcription of vimentin and several mesenchy-
mal genes with transient overexpression of SENP7L, but not the
HP1α interaction-deficient SENP7L mutant (Fig. 4D).
SENP7L also dictates transcription of two epithelial genes,
E-cad and claudin, but independent of HP1α. First, although
SENP7 directs HP1α to several promoters, HP1α is not observed
at the E-cad promoter (Fig. 4A). Second, overexpression of ei-
ther SENP7L or PXVXLdf produces an equivalent E-cad/
claudin mRNA loss (Fig. 4D), suggesting that the HP1α motif is
dispensable for SENP7L’s regulation of epithelial genes. The
pathway for this regulation is currently unknown.
SENP7L induction elicits dedifferentiation of BCa cells to
support a more mesenchymal cell morphology (Fig. 5 E–G).
Consistently, SENP7L potentiates the migratory properties of
stagnant MCF7 control clones while restoring the reduced motility
of shSP7-MCF7 clones (Fig. 6A). Unlike SENP7L, PXVXLdf
cannot (i) elicit de novo mesenchymal gene transcription (Fig. 4D)
or (ii) alter the migratory potential of either control or shSP7-
MCF7 clones (Fig. 6A). Similarly, maintaining a large pool of
hypo-SUMOylated HP1α (K32R) only partially, whereas SENP7L
overexpression completely, rescues the reduced shSP7-MCF7 cells
motility (Fig. 6 B and A, respectively). This is because SENP7L,
unlike PXVXLdf or K32R, affects both “arms” of the EMT
process: (i) mesenchymal gene transcription dependent on HP1α
deSUMOylation, and (ii) inhibiting epithelial gene transcription
independent of HP1α’s SUMOylation state. Hence, reducing the
predominant SENP7L population in GILM2 cells reverts the
EMT response (Fig. S6F) and significantly reduces the invasive,
tumorigenic, and metastatic potential of these BCa cells (Fig. 6
C–F). Collectively the results support that induction of SENP7L
favors BCa cell survival and EMT properties as outlined in Fig. 7.
The present findings warrant the need to investigate the prom-
etastatic/invasive properties of SENP7 further in whole animals.
Materials and Methods
All cell lines were grown and maintained as described in SI Materials and
Methods. University of Texas M. D. Anderson Cancer Center guidelines were
followed for the housing, caring, and use of mice. Detailed protocols for all
experiments are presented in SI Materials and Methods.
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